Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of litifilimab in active systemic lupus erythematosus
jRCT2071210089Phase 3Active, not recruiting
- Sponsor
- Biogen
- Start
- Feb 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial of litifilimab in systemic lupus erythematosus (SLE) (3 arms), sponsored by Biogen. Primary endpoint: SRI-4 response at Week 52. Started Feb 2022; status: active, not recruiting.
02
Drugs
litifilimab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on jRCT2071210089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071210089.